ciprofloxacin has been researched along with Tuberculosis in 61 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Tuberculosis: Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Minimum inhibitory concentrations of sitafloxacin, gatifloxacin, moxifloxacin, sparfloxacin, levofloxacin and ciprofloxacin against 59 ciprofloxacin-resistant clinical isolates of Mycobacterium tuberculosis from Japan were determined." | 7.78 | Sensitivities of ciprofloxacin-resistant Mycobacterium tuberculosis clinical isolates to fluoroquinolones: role of mutant DNA gyrase subunits in drug resistance. ( Kim, H; Matsuba, T; Nakajima, C; Saito, H; Suzuki, Y; Tamaru, A, 2012) |
| "We report three patients who experienced hepatotoxic reactions in association with acetaminophen ingestion while undergoing treatment for active tuberculosis with isoniazid, rifampin, and other agents." | 7.69 | Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. ( Nelson, SD; Nolan, CM; Sandblom, RE; Slattery, JT; Thummel, KE, 1994) |
| "Members of the fluoroquinolone class are being actively evaluated for inclusion in tuberculosis chemotherapy regimens, and we sought to determine the best in vitro and pharmacodynamic predictors of in vivo efficacy in mice." | 5.34 | Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. ( Balasubramanian, V; Bharath, S; Gaonkar, S; Jayaram, R; Jayashree, R; Kaur, P; Mahesh, BN; Nandi, V; Shandil, RK; Suresh, BL, 2007) |
| " We examined the relationship between ciprofloxacin bactericidal activity and the emergence of resistance in an in vitro pharmacodynamic infection model in which we exposed Mycobacterium tuberculosis to simulated free-drug ciprofloxacin serum concentration-time profiles that mimic those encountered in humans treated with ciprofloxacin orally for 2 weeks." | 5.33 | Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. ( Deziel, MR; Drusano, GL; Gumbo, T; Louie, A, 2005) |
| " In order to develop promising antitubercular and antibacterial lead compounds, we designed and synthesized a new series of derivatives of 2-aminothiazole conjugated nitrofuran with activities against both Mycobacterium tuberculosis and Staphylococcus aureus." | 3.83 | Identification of novel 2-aminothiazole conjugated nitrofuran as antitubercular and antibacterial agents. ( Deng, H; Gao, C; Lei, Q; Liu, Z; Peng, C; Ran, K; Shi, Y; Wang, N; Wei, W; Xiao, K; Xiong, L; You, X; Yu, L, 2016) |
| "Seven polycharged species, incorporating 1, 2, 3, 4 and 6 guanidine arms organized around a benzene core were synthesized and assayed as anti-mycobacterial agents against Mycobacterium tuberculosis." | 3.81 | Guanidinium compounds with sub-micromolar activities against Mycobacterium tuberculosis. Synthesis, characterization and biological evaluations. ( Constant, P; Daffé, M; Massimba-Dibama, H; Mourer, M; Regnouf-de-Vains, JB, 2015) |
| "Minimum inhibitory concentrations of sitafloxacin, gatifloxacin, moxifloxacin, sparfloxacin, levofloxacin and ciprofloxacin against 59 ciprofloxacin-resistant clinical isolates of Mycobacterium tuberculosis from Japan were determined." | 3.78 | Sensitivities of ciprofloxacin-resistant Mycobacterium tuberculosis clinical isolates to fluoroquinolones: role of mutant DNA gyrase subunits in drug resistance. ( Kim, H; Matsuba, T; Nakajima, C; Saito, H; Suzuki, Y; Tamaru, A, 2012) |
| "Our data confirm the usefulness of moxifloxacin in the treatment of tuberculosis and suggest that levofloxacin may be used as an alternative drug in the treatment of latent tuberculosis when it is not possible to use isoniazid." | 3.77 | Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model. ( Cremades, R; Galiana, A; García-Pachón, E; López, P; Rodríguez, JC; Royo, G; Ruiz-García, M, 2011) |
| "In an effort to discover new and effective chemotherapeutic agents from this laboratory for the treatment of tuberculosis, here in we describe the synthesis and biological evaluation of a series of novel benzothiadiazine 1,1-dioxide (BTD) based congeners by using rifampicin, streptomycin; ciprofloxacin and amphotericin as positive controls." | 3.76 | Anti-tubercular agents. Part 5: synthesis and biological evaluation of benzothiadiazine 1,1-dioxide based congeners. ( Abdullah, ST; Ahmed, SK; Azeeza, S; Kamal, A; Khan, IA; Reddy, AM; Sharma, S; Shetti, RV; Swapna, P, 2010) |
| "22 microM) and was 3 times more active than standard isoniazid (INH) and equally active as rifampicin (RIF) in log-phase culture of Mycobacterium tuberculosis H37Rv." | 3.75 | 5-Nitrofuran-2-yl derivatives: synthesis and inhibitory activities against growing and dormant mycobacterium species. ( Banerjee, D; Dhakla, P; Manjashetty, TH; Senthilkumar, P; Sriram, D; Yogeeswari, P, 2009) |
| "We report three patients who experienced hepatotoxic reactions in association with acetaminophen ingestion while undergoing treatment for active tuberculosis with isoniazid, rifampin, and other agents." | 3.69 | Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. ( Nelson, SD; Nolan, CM; Sandblom, RE; Slattery, JT; Thummel, KE, 1994) |
| "Patients with the acquired immune deficiency syndrome (AIDS) with disseminated Mycobacterium avium infection have responded poorly to treatment with rifabutine (Ansamycin) and clofazimine, in spite of the good in vitro response of M." | 3.67 | Therapeutic implications of inhibition versus killing of Mycobacterium avium complex by antimicrobial agents. ( Hadley, WK; Nassos, PS; Yajko, DM, 1987) |
| "Ciprofloxacin and ofloxacin were classified as older-generation fluoroquinolones; levofloxacin, moxifloxacin and gatifloxacin were considered newer agents." | 1.39 | Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones. ( Bian, A; Blackman, A; Eden, S; Maruri, F; Mitchel, E; Shintani, AK; Sterling, TR; van der Heijden, YF; Warkentin, JV, 2013) |
| " The cytotoxic effects against mouse fibroblasts (NIH 3T3) in vitro were evaluated for 5c and 5d, which displayed no toxic effects (IC(50) > 1000 μM) against the mouse fibroblast cell line NIH 3T3." | 1.37 | Synthesis of 3-heteroarylthioquinoline derivatives and their in vitro antituberculosis and cytotoxicity studies. ( Chitra, S; Manisankar, P; Muthusubramanian, S; Paul, N; Sriram, D; Yogeeswari, P, 2011) |
| "Members of the fluoroquinolone class are being actively evaluated for inclusion in tuberculosis chemotherapy regimens, and we sought to determine the best in vitro and pharmacodynamic predictors of in vivo efficacy in mice." | 1.34 | Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. ( Balasubramanian, V; Bharath, S; Gaonkar, S; Jayaram, R; Jayashree, R; Kaur, P; Mahesh, BN; Nandi, V; Shandil, RK; Suresh, BL, 2007) |
| " We examined the relationship between ciprofloxacin bactericidal activity and the emergence of resistance in an in vitro pharmacodynamic infection model in which we exposed Mycobacterium tuberculosis to simulated free-drug ciprofloxacin serum concentration-time profiles that mimic those encountered in humans treated with ciprofloxacin orally for 2 weeks." | 1.33 | Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. ( Deziel, MR; Drusano, GL; Gumbo, T; Louie, A, 2005) |
| "The diagnosis of deep seated bacterial infections, such as intra-abdominal abscesses, endocarditis, and osteomyelitis, can be difficult and delayed, thereby compromising effective treatment." | 1.31 | Imaging bacterial infection with (99m)Tc-ciprofloxacin (Infecton). ( Amaral, H; Bhatnagar, A; Britton, KE; Das, SS; Katamihardja, AH; Malamitsi, J; Moustafa, HM; Padhy, AK; Solanki, KK; Soroa, VE; Sundram, FX; Wareham, DW, 2002) |
| "Ciprofloxacin was applied in four different diffusion sources (1, 3, 10 and 30 microg) on a single strip, the M-strip, and used." | 1.31 | MIC determination of fusidic acid and of ciprofloxacin using multidisk diffusion tests. ( Kronvall, G, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (8.20) | 18.7374 |
| 1990's | 7 (11.48) | 18.2507 |
| 2000's | 14 (22.95) | 29.6817 |
| 2010's | 28 (45.90) | 24.3611 |
| 2020's | 7 (11.48) | 2.80 |
| Authors | Studies |
|---|---|
| Shandil, RK | 1 |
| Jayaram, R | 1 |
| Kaur, P | 1 |
| Gaonkar, S | 1 |
| Suresh, BL | 1 |
| Mahesh, BN | 1 |
| Jayashree, R | 1 |
| Nandi, V | 1 |
| Bharath, S | 1 |
| Balasubramanian, V | 1 |
| Sriram, D | 4 |
| Yogeeswari, P | 3 |
| Dhakla, P | 1 |
| Senthilkumar, P | 1 |
| Banerjee, D | 1 |
| Manjashetty, TH | 1 |
| Kamal, A | 1 |
| Shetti, RV | 1 |
| Azeeza, S | 1 |
| Ahmed, SK | 1 |
| Swapna, P | 1 |
| Reddy, AM | 1 |
| Khan, IA | 2 |
| Sharma, S | 1 |
| Abdullah, ST | 1 |
| Chitra, S | 1 |
| Paul, N | 1 |
| Muthusubramanian, S | 1 |
| Manisankar, P | 1 |
| Thomas, KD | 1 |
| Adhikari, AV | 1 |
| Chowdhury, IH | 1 |
| Sandeep, T | 1 |
| Mahmood, R | 1 |
| Bhattacharya, B | 1 |
| Sumesh, E | 1 |
| Karuvalam, RP | 1 |
| Haridas, KR | 1 |
| Nayak, SK | 1 |
| Row, TN | 1 |
| Rajeesh, P | 1 |
| Rishikesan, R | 1 |
| Kumari, NS | 1 |
| Mourer, M | 2 |
| Massimba Dibama, H | 1 |
| Constant, P | 3 |
| Daffé, M | 3 |
| Regnouf-de-Vains, JB | 2 |
| Shelke, SN | 1 |
| Mhaske, GR | 1 |
| Bonifácio, VD | 1 |
| Gawande, MB | 1 |
| Karkare, S | 1 |
| Chung, TT | 1 |
| Collin, F | 1 |
| Mitchenall, LA | 1 |
| McKay, AR | 1 |
| Greive, SJ | 1 |
| Meyer, JJ | 1 |
| Lall, N | 1 |
| Maxwell, A | 1 |
| Jardosh, HH | 1 |
| Patel, MP | 1 |
| Suresh, N | 1 |
| Nagesh, HN | 1 |
| Renuka, J | 1 |
| Rajput, V | 1 |
| Sharma, R | 2 |
| Kondapalli Venkata Gowri, CS | 1 |
| Majewski, MW | 2 |
| Cho, S | 2 |
| Miller, PA | 2 |
| Franzblau, SG | 2 |
| Miller, MJ | 2 |
| Massimba-Dibama, H | 1 |
| Karad, SC | 1 |
| Purohit, VB | 1 |
| Thakor, P | 1 |
| Thakkar, VR | 1 |
| Raval, DK | 1 |
| Tiwari, R | 1 |
| Ran, K | 1 |
| Gao, C | 1 |
| Deng, H | 1 |
| Lei, Q | 1 |
| You, X | 1 |
| Wang, N | 1 |
| Shi, Y | 1 |
| Liu, Z | 1 |
| Wei, W | 1 |
| Peng, C | 1 |
| Xiong, L | 1 |
| Xiao, K | 1 |
| Yu, L | 1 |
| Tanwar, B | 1 |
| Kumar, A | 1 |
| Chakraborti, AK | 1 |
| Salve, PS | 1 |
| Alegaon, SG | 1 |
| Fan, YL | 2 |
| Wu, JB | 1 |
| Cheng, XW | 1 |
| Zhang, FZ | 1 |
| Feng, LS | 3 |
| Jin, XH | 1 |
| Huang, ZP | 1 |
| Yu, HF | 1 |
| Zeng, ZG | 1 |
| Gao, T | 1 |
| Cordeiro, R | 1 |
| Kachroo, M | 1 |
| Sharma, A | 1 |
| Agrahari, AK | 1 |
| Rajkhowa, S | 1 |
| Tiwari, VK | 1 |
| Le, NH | 1 |
| Tranier, S | 1 |
| Nahoum, V | 1 |
| Guillet, V | 1 |
| Maveyraud, L | 1 |
| Mourey, L | 1 |
| Verhaeghe, P | 1 |
| Marrakchi, H | 1 |
| Bhosale, D | 1 |
| Mali, SN | 1 |
| Thorat, BR | 1 |
| Wavhal, SS | 1 |
| Bhagat, DS | 1 |
| Borade, RM | 1 |
| Yohannes, H | 1 |
| Belachew, T | 1 |
| Assefa, M | 1 |
| Getaneh, E | 1 |
| Zeray, H | 1 |
| Kegne, A | 1 |
| Angawu, S | 1 |
| Belay, G | 1 |
| Biset, S | 1 |
| Tigabu, A | 1 |
| Campolattano, N | 1 |
| D'Abrosca, G | 1 |
| Russo, L | 1 |
| De Siena, B | 1 |
| Della Gala, M | 1 |
| De Chiara, I | 1 |
| Marasco, R | 1 |
| Goff, A | 1 |
| Waddell, SJ | 1 |
| Sacco, M | 1 |
| Muscariello, L | 1 |
| Manina, G | 1 |
| Griego, A | 1 |
| Singh, LK | 1 |
| McKinney, JD | 1 |
| Dhar, N | 1 |
| Wang, DY | 1 |
| Yang, G | 1 |
| van der Mei, HC | 1 |
| Ren, Y | 1 |
| Busscher, HJ | 1 |
| Shi, L | 1 |
| Xu, Z | 1 |
| Zhang, S | 1 |
| Li, XN | 1 |
| Huang, GC | 1 |
| Chai, Y | 1 |
| Lv, ZS | 1 |
| Guo, HY | 1 |
| Liu, ML | 1 |
| Yılmaz, FF | 1 |
| Eraç, B | 1 |
| Ermertcan, Ş | 1 |
| Çavuşoğlu, C | 1 |
| Biçmen, C | 1 |
| Aktoğu Özkan, S | 1 |
| Hoşgör Limoncu, M | 1 |
| van der Heijden, YF | 1 |
| Maruri, F | 1 |
| Blackman, A | 1 |
| Mitchel, E | 2 |
| Bian, A | 1 |
| Shintani, AK | 1 |
| Eden, S | 1 |
| Warkentin, JV | 1 |
| Sterling, TR | 3 |
| Kaevska, M | 1 |
| Sterba, J | 1 |
| Svobodova, J | 1 |
| Pavlik, I | 1 |
| Elktaibi, A | 1 |
| Elochi, MR | 1 |
| Sinaa, M | 1 |
| Allaoui, M | 1 |
| Alami, Y | 1 |
| Amrani, M | 1 |
| Kharadi, GJ | 1 |
| Cremades, R | 1 |
| Rodríguez, JC | 1 |
| García-Pachón, E | 1 |
| Galiana, A | 1 |
| Ruiz-García, M | 1 |
| López, P | 1 |
| Royo, G | 1 |
| Suzuki, Y | 1 |
| Nakajima, C | 1 |
| Tamaru, A | 1 |
| Kim, H | 1 |
| Matsuba, T | 1 |
| Saito, H | 1 |
| Ruh, E | 1 |
| Ocal, HY | 1 |
| Yurdakul, P | 1 |
| Sarıbaş, Z | 1 |
| Alp, A | 1 |
| Yuen, KY | 1 |
| Woo, PC | 1 |
| Durek, C | 1 |
| Jurczok, A | 1 |
| Werner, H | 1 |
| Jocham, D | 1 |
| Bohle, A | 1 |
| Britton, KE | 1 |
| Wareham, DW | 1 |
| Das, SS | 1 |
| Solanki, KK | 1 |
| Amaral, H | 1 |
| Bhatnagar, A | 2 |
| Katamihardja, AH | 1 |
| Malamitsi, J | 1 |
| Moustafa, HM | 1 |
| Soroa, VE | 1 |
| Sundram, FX | 1 |
| Padhy, AK | 1 |
| GAEDEKE, R | 1 |
| GREIFENHAGEN, C | 1 |
| Collins, DM | 1 |
| Kawakami, RP | 1 |
| Buddle, BM | 1 |
| Wards, BJ | 1 |
| de Lisle, GW | 1 |
| Ginsburg, AS | 1 |
| Woolwine, SC | 1 |
| Hooper, N | 1 |
| Benjamin, WH | 1 |
| Bishai, WR | 1 |
| Dorman, SE | 1 |
| Gaur, S | 1 |
| Trayner, E | 1 |
| Aish, L | 1 |
| Weinstein, R | 1 |
| Gumbo, T | 1 |
| Louie, A | 1 |
| Deziel, MR | 1 |
| Drusano, GL | 1 |
| Bhusal, Y | 1 |
| Shiohira, CM | 1 |
| Yamane, N | 1 |
| Tewari, KN | 1 |
| Mondal, A | 1 |
| Mishra, AK | 1 |
| Singh, AK | 1 |
| Chopra, MK | 1 |
| Rawat, H | 1 |
| Kashyap, R | 1 |
| Tripathi, RP | 1 |
| Gaba, PD | 1 |
| Haley, C | 1 |
| Griffin, MR | 1 |
| Warkentin, J | 1 |
| Holt, E | 1 |
| Baggett, P | 1 |
| Nolan, CM | 1 |
| Sandblom, RE | 1 |
| Thummel, KE | 1 |
| Slattery, JT | 1 |
| Nelson, SD | 1 |
| Gillespie, SH | 1 |
| Kennedy, N | 1 |
| Takiff, HE | 1 |
| Salazar, L | 1 |
| Guerrero, C | 1 |
| Philipp, W | 1 |
| Huang, WM | 1 |
| Kreiswirth, B | 1 |
| Cole, ST | 1 |
| Jacobs, WR | 1 |
| Telenti, A | 1 |
| Wallace, RJ | 1 |
| Dunbar, D | 1 |
| Brown, BA | 1 |
| Onyi, G | 1 |
| Dunlap, R | 1 |
| Ahn, CH | 1 |
| Murphy, DT | 1 |
| Eltringham, IJ | 1 |
| Wilson, SM | 1 |
| Drobniewski, FA | 1 |
| Vacher, S | 1 |
| Pellegrin, JL | 1 |
| Leblanc, F | 1 |
| Fourche, J | 1 |
| Maugein, J | 1 |
| Kronvall, G | 1 |
| Khilnani, G | 1 |
| Gupta, RC | 1 |
| Richter, E | 1 |
| Wessling, J | 1 |
| Lügering, N | 1 |
| Domschke, W | 1 |
| Rüsch-Gerdes, S | 1 |
| Wurtz, RM | 1 |
| Abrams, D | 1 |
| Becker, S | 1 |
| Jacobson, MA | 1 |
| Mass, MM | 1 |
| Marks, SH | 1 |
| Andriole, VT | 1 |
| Chadwick, M | 1 |
| Nicholson, G | 1 |
| Gaya, H | 1 |
| Yajko, DM | 1 |
| Nassos, PS | 1 |
| Hadley, WK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Clarithromycin or Moxifloxacin Containing Regimen in 6 Months Sputum Conversion of Mycobacterium Xenopi[NCT01298336] | Phase 3 | 92 participants (Actual) | Interventional | 2011-03-02 | Completed | ||
| A Randomized Controlled Non-Inferiority Study for Shortening Tuberculosis Treatment With Sitafloxacin-Containing Regimens[NCT05454345] | Phase 3 | 620 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for ciprofloxacin and Tuberculosis
| Article | Year |
|---|---|
Fluoroquinolone derivatives and their anti-tubercular activities.
Topics: Animals; Antitubercular Agents; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Molecula | 2018 |
Recent advances of imidazole-containing derivatives as anti-tubercular agents.
Topics: Animals; Antitubercular Agents; Dose-Response Relationship, Drug; Humans; Imidazoles; Microbial Sens | 2018 |
Emerging impact of triazoles as anti-tubercular agent.
Topics: Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Structure-Ac | 2022 |
Tuberculosis in blood and marrow transplant recipients.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Bone Marrow Transplantation; Ciprofloxacin; Female; Graft vs | 2002 |
57 other studies available for ciprofloxacin and Tuberculosis
| Article | Year |
|---|---|
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Ciprofloxacin; Dose-Response R | 2007 |
5-Nitrofuran-2-yl derivatives: synthesis and inhibitory activities against growing and dormant mycobacterium species.
Topics: Antitubercular Agents; Combinatorial Chemistry Techniques; Microbial Sensitivity Tests; Mycobacteriu | 2009 |
Anti-tubercular agents. Part 5: synthesis and biological evaluation of benzothiadiazine 1,1-dioxide based congeners.
Topics: Animals; Antitubercular Agents; Bacteria; Benzothiadiazines; Cell Line; Cell Survival; Female; Fungi | 2010 |
Synthesis of 3-heteroarylthioquinoline derivatives and their in vitro antituberculosis and cytotoxicity studies.
Topics: Animals; Antitubercular Agents; Humans; Mice; Microbial Sensitivity Tests; Models, Molecular; Mycoba | 2011 |
Design, synthesis and docking studies of quinoline-oxazolidinone hybrid molecules and their antitubercular properties.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Bacteria; Catalytic Domain; Drug Design; Enoyl-(Acyl-C | 2011 |
Design, synthesis of some new (2-aminothiazol-4-yl)methylester derivatives as possible antimicrobial and antitubercular agents.
Topics: Anti-Infective Agents; Antitubercular Agents; Bacteria; Bacterial Infections; Crystallography, X-Ray | 2012 |
Anti-mycobacterial activities of some cationic and anionic calix[4]arene derivatives.
Topics: 2,2'-Dipyridyl; Anions; Antitubercular Agents; Calixarenes; Guanidine; Humans; Inhibitory Concentrat | 2012 |
Green synthesis and anti-infective activities of fluorinated pyrazoline derivatives.
Topics: Anti-Infective Agents; Antitubercular Agents; Bacteria; Bacterial Infections; Fungi; Green Chemistry | 2012 |
The naphthoquinone diospyrin is an inhibitor of DNA gyrase with a novel mechanism of action.
Topics: Adenosine Triphosphate; Anti-Infective Agents; Binding Sites; Catalytic Domain; DNA; DNA Gyrase; Esc | 2013 |
Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Antitubercular Agents; Artemia; Bacteria; Dose-Re | 2013 |
Synthesis and evaluation of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-(2-(4-substitutedpiperazin-1-yl)acetyl)piperazin-1-yl)quinoline-3-carboxylic acid derivatives as anti-tubercular and antibacterial agents.
Topics: Anti-Bacterial Agents; Carboxylic Acids; Escherichia coli; Escherichia coli Infections; Halogenation | 2014 |
Syntheses and evaluation of substituted aromatic hydroxamates and hydroxamic acids that target Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Dose-Response Relationship, Drug; Hydrocarbons, Aromatic; Hydroxamic Acids; M | 2015 |
Guanidinium compounds with sub-micromolar activities against Mycobacterium tuberculosis. Synthesis, characterization and biological evaluations.
Topics: Antitubercular Agents; Guanidine; Humans; Models, Molecular; Mycobacterium tuberculosis; Tuberculosi | 2015 |
Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.
Topics: Anti-Infective Agents; Antimalarials; Antitubercular Agents; Bacteria; Bacterial Infections; Fungi; | 2016 |
Design, syntheses, and anti-tuberculosis activities of conjugates of piperazino-1,3-benzothiazin-4-ones (pBTZs) with 2,7-dimethylimidazo [1,2-a]pyridine-3-carboxylic acids and 7-phenylacetyl cephalosporins.
Topics: Antitubercular Agents; Dose-Response Relationship, Drug; Drug Design; Imidazoles; Microbial Sensitiv | 2016 |
Identification of novel 2-aminothiazole conjugated nitrofuran as antitubercular and antibacterial agents.
Topics: Animals; Anti-Bacterial Agents; Chlorocebus aethiops; Dose-Response Relationship, Drug; Microbial Se | 2016 |
Design, development of new synthetic methodology, and biological evaluation of substituted quinolines as new anti-tubercular leads.
Topics: Antitubercular Agents; Dose-Response Relationship, Drug; Drug Design; HEK293 Cells; Humans; Microbia | 2016 |
Three-component, one-pot synthesis of anthranilamide Schiff bases bearing 4-aminoquinoline moiety as Mycobacterium tuberculosis gyrase inhibitors.
Topics: Aminoquinolines; Animals; Antitubercular Agents; DNA Gyrase; Humans; Microbial Sensitivity Tests; My | 2017 |
Synthesis and biological evaluation of anti-tubercular activity of Schiff bases of 2-Amino thiazoles.
Topics: Amination; Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; S | 2020 |
Drug screening approach against mycobacterial fatty acyl-AMP ligase FAAL32 renews the interest of the salicylanilide pharmacophore in the fight against tuberculosis.
Topics: Adenosine Monophosphate; Antitubercular Agents; Drug Evaluation, Preclinical; Humans; Mycobacterium | 2022 |
Synthesis, Molecular Docking, and
Topics: Antitubercular Agents; Ciprofloxacin; Ethanol; Humans; Hydrazones; Isoniazid; Molecular Docking Simu | 2022 |
Pathogenic bacteria recovered from Gene X-pert tuberculosis-negative adult patients in Gondar, Northwest Ethiopia.
Topics: Adult; Anti-Bacterial Agents; Bacteria; Cefoxitin; Ciprofloxacin; Cross-Sectional Studies; Escherich | 2023 |
Insight into the on/off switch that regulates expression of the MSMEG-3762/63 efflux pump in Mycobacterium smegmatis.
Topics: Bacterial Proteins; Ciprofloxacin; Humans; Mycobacterium smegmatis; Mycobacterium tuberculosis; Rifa | 2023 |
Preexisting variation in DNA damage response predicts the fate of single mycobacteria under stress.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; DNA Damage; Humans; Microfluidics; Mycobac | 2019 |
Liposomes with Water as a pH-Responsive Functionality for Targeting of Acidic Tumor and Infection Sites.
Topics: Acetates; Animals; Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Drug Carriers; Female; Fluorescen | 2021 |
Synthesis and In Vitro Antimycobacterial and Antibacterial Activity of 8-OMe Ciprofloxacin-Hydrozone/Azole Hybrids.
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Azoles; Ciprofloxacin; Humans; Hydrozoa; Micr | 2017 |
In vitro effects of ciprofloxacin, levofloxacin and moxifloxacin on Mycobacterium tuberculosis isolates.
Topics: Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity | 2018 |
Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones.
Topics: Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Case-Control Studies; Ciprofloxacin; DNA Gyrase; | 2013 |
Mycobacterium avium subsp. avium and Mycobacterium neoaurum detection in an immunocompromised patient.
Topics: Adolescent; Antineoplastic Agents; Antitubercular Agents; Ciprofloxacin; Environmental Microbiology; | 2014 |
[Pseudotumoral malakoplakia of the breast].
Topics: Breast Neoplasms; Ciprofloxacin; Female; Humans; Malacoplakia; Middle Aged; Tuberculosis | 2015 |
Antitubercular and fluorescence studies of copper(II) complexes with quinolone family member, ciprofloxacin.
Topics: Antitubercular Agents; Ciprofloxacin; Copper; Crystallography, X-Ray; Fluorescence; Models, Molecula | 2011 |
Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model.
Topics: Antitubercular Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; H | 2011 |
Sensitivities of ciprofloxacin-resistant Mycobacterium tuberculosis clinical isolates to fluoroquinolones: role of mutant DNA gyrase subunits in drug resistance.
Topics: Amino Acid Substitution; Antitubercular Agents; Ciprofloxacin; DNA Gyrase; DNA, Bacterial; Drug Resi | 2012 |
[Evaluation of Tetrazolium Violet and Resazurin Assays for Ciprofloxacin Susceptibility Testing of Resistant Mycobacterium tuberculosis Isolates].
Topics: Antitubercular Agents; Ciprofloxacin; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosi | 2013 |
Optimal treatment of systemic bacillus Calmette-Guérin infection: investigations in an animal model.
Topics: Animals; Cell Survival; Ciprofloxacin; Disease Models, Animal; Dose-Response Relationship, Drug; Dru | 2002 |
Imaging bacterial infection with (99m)Tc-ciprofloxacin (Infecton).
Topics: Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Child; Child, Preschool; | 2002 |
[STUDIES ON SOURCES OF INFECTON IN CHILDHOOD TUBERCULOSIS].
Topics: Adolescent; BCG Vaccine; Child; Ciprofloxacin; Germany; Germany, West; Humans; Infant; Infant, Newbo | 1964 |
Different susceptibility of two animal species infected with isogenic mutants of Mycobacterium bovis identifies phoT as having roles in tuberculosis virulence and phosphate transport.
Topics: Animals; Bacterial Proteins; Base Sequence; Cattle; Ciprofloxacin; Disease Models, Animal; Female; G | 2003 |
The rapid development of fluoroquinolone resistance in M. tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, | 2003 |
Bronchus-associated lymphoid tissue lymphoma arising in a patient with bronchiectasis and chronic Mycobacterium avium infection.
Topics: Aged; Anti-Infective Agents; Bronchial Neoplasms; Bronchiectasis; Chronic Disease; Ciprofloxacin; Cl | 2004 |
Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance.
Topics: Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Microbia | 2005 |
Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Ciprofloxacin; Clarithrom | 2005 |
Tc-99m ciprofloxacin scans for detection of tubercular bone infection.
Topics: Adolescent; Adult; Bone Diseases; Ciprofloxacin; Diagnosis, Differential; False Positive Reactions; | 2007 |
Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease.
Topics: Adult; Aged; Ciprofloxacin; Female; Fluoroquinolones; Humans; Logistic Models; Male; Middle Aged; Mu | 2007 |
Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis.
Topics: Acetaminophen; Adult; Capreomycin; Ciprofloxacin; Drug Combinations; Drug Overdose; Ethambutol; Fema | 1994 |
Early bactericidal activity as a method of assessment of drugs for the treatment of tuberculosis.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Evaluation, Preclinical; Isoniazid; Microbial Sensitivity | 1994 |
Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations.
Topics: Anti-Infective Agents; Base Sequence; Ciprofloxacin; Cloning, Molecular; DNA Topoisomerases, Type II | 1994 |
Rifampin-resistant Mycobacterium kansasii.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Antitubercular Agents; Ciprofloxacin; Clinical Protocols; | 1994 |
Evaluation of a bacteriophage-based assay (phage amplified biologically assay) as a rapid screen for resistance to isoniazid, ethambutol, streptomycin, pyrazinamide, and ciprofloxacin among clinical isolates of Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Ciprofloxacin; Drug Resistance, Microbial; Ethambutol; Evaluation Studies as | 1999 |
Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Fluoroquinolones; Humans; Macrophages | 1999 |
MIC determination of fusidic acid and of ciprofloxacin using multidisk diffusion tests.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Fusidic Acid; Gram-Negative Bacteria; G | 2000 |
Inadvertent use of ciprofloxacin as a single agent in undiagnosed tuberculosis.
Topics: Anti-Infective Agents; Ciprofloxacin; Humans; India; Microbial Sensitivity Tests; Mycobacterium tube | 1998 |
Mycobacterium avium subsp. paratuberculosis infection in a patient with HIV, Germany.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antitubercular Agents; Ciproflo | 2002 |
Anaphylactoid drug reactions to ciprofloxacin and rifampicin in HIV-infected patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anaphylaxis; Ciprofloxacin; Humans; Male; Rifampin; Tuber | 1989 |
An update on the efficacy of ciprofloxacin in animal models of infection.
Topics: Abscess; Animals; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Endocarditis, Bacteri | 1989 |
Combination chemotherapy with ciprofloxacin for infection with Mycobacterium tuberculosis in mouse models.
Topics: Animals; Ciprofloxacin; Disease Models, Animal; Drug Therapy, Combination; Isoniazid; Male; Mice; Ri | 1989 |
Therapeutic implications of inhibition versus killing of Mycobacterium avium complex by antimicrobial agents.
Topics: Acquired Immunodeficiency Syndrome; Ciprofloxacin; Clofazimine; Humans; Mycobacterium avium; Rifabut | 1987 |